DDL, a third-party testing laboratory specialising in medical device and pharmaceutical packaging, combination products, and materials testing, announced on Tuesday that it has launched a new Pharmaceutical Consulting Services programme designed to help pharmaceutical and drug delivery companies navigate complex development challenges, reduce risk and accelerate product development.
The new consulting services provide expert guidance across pharmaceutical primary packaging, containment and delivery systems, and combination products. By integrating technical consulting with DDL's established laboratory testing capabilities, the services aim to help companies develop effective, phase-appropriate testing strategies and address potential challenges before they lead to costly rework or delays.
"Decisions made early in pharmaceutical packaging and drug delivery development can have significant implications for product performance, quality and regulatory success," said Jennifer Riter, vice president of Analytical Testing Services at DDL. "Our goal is to help customers make informed technical decisions, identify potential risks and develop testing strategies that support successful product development from initial concept through commercialisation."
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme